Search
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. … WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers.
Categories: Compounds used in a research, industrial, or household settingGastric intrinsic factor
go.drugbank.com/drugs/DB09349Approvedon in the small intestine. … However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias
Mixtures: EnLyte Extra-LNFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalThe manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use … [A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout.
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigationalthe median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration. … [L2933] It is administered orally and is odorless, tasteless, and stable at room temperature.
Categories: Compounds used in a research, industrial, or household setting, Ion Exchange ResinsSitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalSitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256 … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].
Categories: Drugs Used in Diabetes, DPP-IV InhibitorsSpinosad
go.drugbank.com/drugs/DB08823ApprovedVet approvedSpinosad is a pediculicide mixture of spinosyn A and spinosyn D (in an approximately 5:1 ratio, respectively) used in the topical treatment of head lice in children (four years old and older) and in adults … Spinosad is an insecticide based on a compound found in S. spinosa, a bacterial species.
Categories: Compounds used in a research, industrial, or household settingTeplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigationalTeplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients
Categories: Drugs Used in DiabetesNitrofurantoin
go.drugbank.com/drugs/DB00698ApprovedInvestigationalVet approved[A179824] Nitrofurantoin is a second line treatment to [trimethoprim]/[sulfamethoxazole].[A179830] Nitrofurantoin was granted FDA approval on 6 February 1953.[L6895] … [A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.
Synonyms: N-(5-Nitrofurfurylidene)-1-aminohydantoinUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. … More recently, it has also been approved for the treatment of giant cell arteritis in adults and active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.[L10896]
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. … [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.